Evaluating adverse events of pegvaliase-pqpz in phenylketonuria treatment: A comprehensive safety assessment
Objectives: In 2018, the Food and Drug Administration approved pegvaliase-pqpz as an enzyme replacement therapy to lower blood phenylalanine levels in adults with phenylketonuria. However, its potential side effects have not been fully explored in a real-world setting. This study aimed to examine pe...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-04-01
|
| Series: | SAGE Open Medicine |
| Online Access: | https://doi.org/10.1177/20503121251330187 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!